NASDAQ:TGTX - TG Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.00
  • Forecasted Upside: 45.82 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$43.89
▲ +0.39 (0.90%)
1 month | 3 months | 12 months
Get New TG Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TGTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$64.00
▲ +45.82% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $64.00, with a high forecast of $95.00 and a low forecast of $38.00. The average price target represents a 45.82% upside from the last price of $43.89.
Buy
The current consensus among 5 polled investment analysts is to buy stock in TG Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2021HC WainwrightBoost Price TargetBuy$78.00 ➝ $79.00Medium
i
2/5/2021B. RileyBoost Price TargetBuy$90.00 ➝ $95.00High
i
Rating by Mayank Mamtani at B. Riley
1/19/2021HC WainwrightBoost Price TargetBuy$61.00 ➝ $78.00Low
i
12/10/2020HC WainwrightBoost Price TargetBuy$38.00 ➝ $61.00High
i
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $48.00Low
i
9/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
i
8/11/2020HC WainwrightBoost Price TargetBuy$32.00 ➝ $38.00Medium
i
Rating by Edward White at HC Wainwright
8/10/2020B. RileyReiterated RatingBuy$37.00Medium
i
Rating by Mayank Mamtani at B. Riley
6/15/2020B. RileyReiterated RatingBuy$37.00Low
i
Rating by Mayank Mamtani at B. Riley
6/5/2020Evercore ISIInitiated CoverageOutperform$60.00High
i
6/1/2020B. RileyReiterated RatingBuy$37.00High
i
Rating by Mayank Mamtani at B. Riley
5/29/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Edward White at HC Wainwright
5/18/2020HC WainwrightReiterated RatingBuy$32.00Medium
i
Rating by Edward White at HC Wainwright
5/17/2020B. RileyBoost Price TargetBuy$29.00 ➝ $37.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/12/2020HC WainwrightReiterated RatingBuy$32.00Medium
i
Rating by Edward White at HC Wainwright
5/6/2020Cantor FitzgeraldBoost Price TargetOverweight$19.00 ➝ $35.00High
i
5/6/2020B. RileyBoost Price TargetBuy$25.00 ➝ $29.00High
i
Rating by Mayank Mamtani at B. Riley
5/5/2020HC WainwrightBoost Price TargetBuy$24.00 ➝ $32.00High
i
Rating by Edward White at HC Wainwright
4/17/2020B. RileyReiterated RatingBuy$25.00High
i
Rating by Mayank Mamtani at B. Riley
1/17/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $24.00High
i
Rating by Edward White at HC Wainwright
12/10/2019HC WainwrightReiterated RatingBuy$20.00High
i
11/27/2019B. RileyInitiated CoverageBuy$12.00High
i
Rating by Mayank Mamtani at B. Riley
11/12/2019HC WainwrightReiterated RatingBuy$20.00Medium
i
10/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
i
6/11/2019B. RileyReiterated RatingBuyMedium
i
Rating by H. Polishetty at B. Riley
5/13/2019Cantor FitzgeraldReiterated RatingBuy$17.00High
i
Rating by A. Young at Cantor Fitzgerald
4/12/2019HC WainwrightReiterated RatingBuy$20.00Low
i
3/29/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00High
i
Rating by A. Young at Cantor Fitzgerald
2/6/2019Jefferies Financial GroupReiterated RatingBuy$8.00High
i
1/22/2019HC WainwrightReiterated RatingBuyHigh
i
1/8/2019B. RileyInitiated CoverageBuy$10.00Low
i
11/12/2018HC WainwrightReiterated RatingBuy$20.00High
i
11/2/2018HC WainwrightReiterated RatingBuy$21.00Medium
i
9/26/2018LADENBURG THALM/SH SHSet Price TargetBuy$27.00N/A
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
9/25/2018Raymond JamesDowngradeStrong-Buy ➝ Outperform$22.00 ➝ $12.00High
i
8/7/2018HC WainwrightReiterated RatingBuy$38.00High
i
4/25/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Reni Benjamin at Raymond James
4/19/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Reni Benjamin at Raymond James
3/9/2018B. RileyReiterated RatingBuy ➝ Buy$21.50 ➝ $27.00Medium
i
Rating by M. Kumar at B. Riley
1/17/2018B. RileyReiterated RatingBuy$21.50Low
i
Rating by M. Kumar at B. Riley
1/16/2018HC WainwrightReiterated RatingBuy$33.00Low
i
Rating by E. White at HC Wainwright
1/8/2018HC WainwrightReiterated RatingBuy$33.00Low
i
Rating by E. White at HC Wainwright
12/12/2017Raymond JamesReiterated RatingBuyLow
i
Rating by Reni Benjamin at Raymond James
12/11/2017HC WainwrightReiterated RatingBuy$33.00High
i
Rating by E. White at HC Wainwright
12/11/2017B. RileyReiterated RatingBuy$21.50High
i
Rating by M. Kumar at B. Riley
12/1/2017B. RileyInitiated CoverageBuy ➝ Buy$21.50High
i
Rating by M. Kumar at B. Riley
11/14/2017HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $33.00N/A
i
Rating by E. White at HC Wainwright
10/3/2017SunTrust BanksReiterated RatingBuy$28.00Medium
i
6/17/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Edward White at (FBRC)
6/5/2017Jefferies Financial GroupReiterated RatingBuy$23.00Medium
i
5/18/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Edward White at (FBRC)
5/1/2017(FBRC)Reiterated RatingBuyLow
i
Rating by Edward White at (FBRC)
4/25/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$23.00High
i
4/21/2017Raymond JamesReiterated RatingBuyHigh
i
Rating by Reni Benjamin at Raymond James
3/13/2017SunTrust BanksSet Price TargetBuy$28.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
3/8/2017LADENBURG THALM/SH SHSet Price TargetBuy$30.00Low
i
Rating by Matthew Kaplan at LADENBURG THALM/SH SH
3/7/2017HC WainwrightReiterated RatingBuy$18.00N/A
i
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 ➝ $30.00N/A
i
3/6/2017(FBRC)Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $26.00N/A
i
Rating by Edward White at (FBRC)
2/22/2017AegisInitiated CoverageBuy$26.00N/A
i
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
12/6/2016(FBRC)Set Price TargetBuy$24.00N/A
i
Rating by Edward White at (FBRC)
11/8/2016Roth CapitalReiterated RatingBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/27/2016Roth CapitalSet Price TargetBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/20/2016Roth CapitalSet Price TargetBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
10/15/2016HC WainwrightReiterated RatingBuy$22.00 ➝ $18.00N/A
i
10/15/2016LADENBURG THALM/SH SHReiterated RatingBuy$28.00N/A
i
10/14/2016Roth CapitalReiterated RatingBuy$33.00N/A
i
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
9/19/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
8/24/2016S&P Equity ResearchLower Price Target$7.15 ➝ $6.40N/A
i
8/10/2016Roth CapitalReiterated RatingBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
6/13/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
6/13/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
6/9/2016Roth CapitalReiterated RatingBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
6/7/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
5/31/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
5/27/2016SunTrust BanksInitiated CoverageBuy ➝ Buy$7.22 ➝ $18.00N/A
i
5/19/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
5/4/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
4/14/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Edward White at (FBRC)
3/10/2016HC WainwrightReiterated RatingBuy$22.00N/A
i
3/8/2016Roth CapitalReiterated RatingBuy$33.00N/A
i
Rating by Joseph Pantginis at Roth Capital
3/8/2016Brean CapitalReiterated RatingBuy$28.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
(Data available from 2/26/2016 forward)
TG Therapeutics logo
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $43.89
$42.57
$44.79

50 Day Range

MA: $49.56
$44.73
$54.30

52 Week Range

Now: $43.89
$6.34
$56.74

Volume

13,667 shs

Average Volume

1,550,894 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

The following Wall Street sell-side analysts have issued reports on TG Therapeutics in the last year: B. Riley, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for TGTX.

What is the current price target for TG Therapeutics?

5 Wall Street analysts have set twelve-month price targets for TG Therapeutics in the last year. Their average twelve-month price target is $64.00, suggesting a possible upside of 44.4%. B. Riley has the highest price target set, predicting TGTX will reach $95.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $38.00 for TG Therapeutics in the next year.
View the latest price targets for TGTX.

What is the current consensus analyst rating for TG Therapeutics?

TG Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TGTX will outperform the market and that investors should add to their positions of TG Therapeutics.
View the latest ratings for TGTX.

What other companies compete with TG Therapeutics?

How do I contact TG Therapeutics' investor relations team?

TG Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is 212-554-4484 and its investor relations email address is [email protected] The official website for TG Therapeutics is www.tgtherapeutics.com.